Open AccessNon‐invasive estimation of 10 B‐4‐borono‐L‐phenylalanine‐derived boron concentration in tumors by PET using 4‐borono‐2‐ 18 F‐fluoro‐phenylalanine
Author(s) -
Yoshimoto Mitsuyoshi,
Honda Natsuki,
Kurihara Hiroaki,
Hiroi Kenta,
Nakamura Satoshi,
Ito Masashi,
Shikano Naoto,
Itami Jun,
Fujii Hirofumi
Publication year - 2018
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.13553
Subject(s) - phenylalanine , chemistry , boron , amino acid transporter , biodistribution , amino acid , radiochemistry , transporter , pharmacology , in vitro , biochemistry , medicine , organic chemistry , gene
In boron neutron capture therapy ( BNCT ), 10 B‐4‐borono‐L‐phenylalanine ( BPA ) is commonly used as a 10 B carrier. PET using 4‐borono‐2‐ 18 F‐fluoro‐phenylalanine ( 18 F‐ FBPA PET ) has been performed to estimate boron concentration and predict the therapeutic effects of BNCT ; however, the association between tumor uptake of 18 F‐ FBPA and boron concentration in tumors remains unclear. The present study investigated the transport mechanism of 18 F‐ FBPA and BPA , and evaluated the utility of 18 F‐ FBPA PET in predicting boron concentration in tumors. The transporter assay revealed that 2‐aminobicyclo‐(2.2.1)‐heptane‐2‐carboxylic acid, an inhibitor of the L‐type amino acid transporter, significantly inhibited 18 F‐ FBPA and 14 C‐4‐borono‐L‐phenylalanine ( 14 C‐ BPA ) uptake in FaDu and LN ‐229 human cancer cells. 18 F‐ FBPA uptake strongly correlated with 14 C‐ BPA uptake in 7 human tumor cell lines ( r = .93; P < .01). PET experiments demonstrated that tumor uptake of 18 F‐ FBPA was independent of the administration method, and uptake of 18 F‐ FBPA by bolus injection correlated well with BPA uptake by continuous intravenous infusion. The results of this study revealed that evaluating tumor uptake of 18 F‐ FBPA by PET was useful for estimating 10 B concentration in tumors.